GAAPP Research: December 2023

Celldex Clinical Trial
for Chronic Inducible Urticaria

For adults with certain types of chronic inducible urticaria (CIndU), the burning, itching, swelling, and pain of chronic hives is a constant challenge. For many, even a daily antihistamine isn’t enough to provide relief from symptoms triggered by cold temperatures (Cold Urticaria) or when the skin is rubbed or scratched (Symptomatic Dermographism).

This clinical research study is now accepting volunteers to help evaluate the effectiveness and safety of an investigational medication given by injection for patients with these types of symptoms.

GAAPP is collaborating with Celldex to bring this opportunity to Chronic Inducible Urticaria to patients in Germany, Poland, Spain, and the United States of America.

How do I participate? 

Check this link with the trial locations and the links to learn more and register to get more information on the trial

Asthma and COPD
Patient and Carer Survey

We hope you are willing to answer a few questions about living with asthma and/or COPD so we can support education programs that help you (or the person you care for) have better communication and interactions with doctors and other healthcare providers

This survey is anonymous, and your personal identifying information will not be collected.

GSK has commissioned COPDF, GAAPP with hosting the survey, and we thank them for hosting access to this survey through their websites.

How do I participate? 

Check this link to access the survey.

Asthma and Allergic Bronchopulmonary Aspergillosis (ABPA)

Do you have asthma?

Have you been diagnosed with asthma and Allergic Bronchopulmonary Aspergillosis (ABPA)? ABPA is an allergy or sensitivity to a fungus found in our environment known as Aspergillus fumigatus. Symptoms may include wheezing, coughing and shortness of breath.

Volunteers are needed for a clinical research study to test whether an inhaled investigational medication may be safe and effective in patients with ABPA.

You may be able to participate if you:

• Are over the age of 18 years
• Have a confirmed diagnosis of asthma and ABPA
• Have been on a stable asthma medication regimen
• Have had an exacerbation (worsening breathing problems) in the last 12 months

The study consists of a screening period up to 4-weeks in duration, followed by a 4-month treatment period and a 2-month follow-up period. The treatment period is double-blind, which means the participants and the study team, including site staff, will not know whether the participants are receiving investigational medication or placebo.

Qualified participants may receive compensation for their time and travel accommodation will be provided as needed.

How do I participate? 

Check this link with the trial locations and contacts.